WEKO3
アイテム
C-11 Methionine Positron Emission Tomography and survival in patients with lung carcinoma treated by carbon ion radiotherapy
https://repo.qst.go.jp/records/60927
https://repo.qst.go.jp/records/609273b7548a2-816a-4f37-8c59-25ac9f881909
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2005-05-13 | |||||
タイトル | ||||||
タイトル | C-11 Methionine Positron Emission Tomography and survival in patients with lung carcinoma treated by carbon ion radiotherapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Goudarzi, Behnaz
× Goudarzi, Behnaz× Yoshikawa, Kyosan× Ishikawa, Hiroyuki× Baba, Masayuki× Miyamoto, Tadaaki× Kandatsu, Susumu× Suzuki, Kazutoshi× Tsujii, Hirohiko× Goudarzi Behnaz× 吉川 京燦× 石川 博之× 馬場 雅行× 宮本 忠昭× 神立 進× 鈴木 和年× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: Carcinoma of the lung is one of the most frequent malignancies and a major cause of mortality. In Japan, according to the study performed by Department of Cancer Control and Statistics in 1998, Lung was the leading site of cancer deaths. In National institute of Radiological Sciences(NIRS), we performed carbon ion radiotherapy(CIRT) for lung cancer patients who were not candidates for surgical resection due to medical reasons or patient refusal. We evaluated whether or not C-11 Methionine(MET) uptake in original tumor before and after CIRT was the early survival predictor factor.We also assess the effect of maximum uptake in lymph node which suspected cantain tumor cells,the number of lymph nodes and residual tumor index in the outcome of lung cancer patients. Methods: MET-PET scan was prospectively performed in 66 patients with lung carcinoma from 1999 to 2002 before and after CIRT. Patients were followed for 3.5 to 53 months (mean:8.04 months) after CIRT. Tumor and suspected lymph nodes MET uptake were measured with a semiquantitative Tumor-to-muscle ratio(TMR) and lymph node-to-muscle ratio(LMR). The MET uptake in the tumor and lymph nodes and the result of short term prognosis were entered in to Kaplan-Meier analysis. The relationship between the number of suspected lymph nodes before CIRT and residual tumor index(after CIRT TMR/bifore CIRT TMR *100) with patients, survival, were also analyzed. Results: The overall median survival time was 19.6 months. No statistically significant difference of survival rate was observed between before and after CIRT Tumor-to-muscle ratio. Better prognosis was observed in patients with residual tumor index < 10% than patients in higher residual tumor index level (2-year survival rate: 58.0% versus 42.0%, P < 0.021). Patients with a baseline maximum lymph node-to-muscle ratio < 4.4 had a significant better survival than patients with a baseline lymph node-to-muscle ratio > 4.4 (2-year survival rate: 64.5% versus 35.5%, P < 0.0001). Patients with three suspected lymph nodes or less had a better survival than more than three lymph nodes (2-year survival rate: 62.4% versus 34.6%, P<0.032). Conclusion: These results suggest that before and after CIRT Tumor-to-muscle ratio seems to be not useful predictor of survival in patients with lung carcinoma. Residual tumor index, pretreatment maximum lymph node-to-muscle ratio and numberof suspected lymph nodes have patential values for predecting survivla in patients with lung carcinoma. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Australian and New Zealand Society of Nuclear Medicine 35th Annual Scientific Meeting | |||||
発表年月日 | ||||||
日付 | 2005-05-02 | |||||
日付タイプ | Issued |